Michael Taylor: Company and FDA data on CAPR efficacy are conflicting and shocking

Michael Taylor: Company and FDA data on CAPR efficacy are conflicting and shocking
CAPR and FDA data called conflicting

Michael Taylor, co-founder / portfolio manager at Agora Trading, expressed serious concerns about CAPR, calling the efficacy data presented by the company and the analysis by the FDA both conflicting and shocking.

Taylor pointed out that discrepancies exist in documents released today and questioned the reliability of the information provided.

Taylor has scrutinized market volatility across sectors in previous commentary. He recently examined whether an AI sector rally could drive a selloff in the XBI biotech ETF. Taylor also described unusual single-name volatility in a Kospi trading session, citing unique market conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.